VERASTEM INC (VSTM) Stock Price, Quote, News and Overview
NASDAQ:VSTM - Nasdaq - US92337C2035 - Common Stock - Currency: USD
VSTM Quote, Performance and Key Statistics
VERASTEM INC
NASDAQ:VSTM (2/5/2025, 11:48:16 AM)
5.85
-0.02 (-0.34%)
The current stock price of VSTM is 5.85 USD. In the past month the price decreased by -16.14%. In the past year, price decreased by -55.6%.
VSTM Latest News, Press Releases and Analysis
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VSTM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.93 | 338.55B | ||
| AMGN | AMGEN INC | 15.35 | 163.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 955.78 | 125.53B | ||
| GILD | GILEAD SCIENCES INC | 22.53 | 124.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.45 | 77.46B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.86B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.42B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.41B | ||
| NTRA | NATERA INC | N/A | 23.35B | ||
| BIIB | BIOGEN INC | 8.94 | 21.28B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.71 | 15.97B |
Related stock screener links
About VSTM
Company Profile
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).
Company Info
VERASTEM INC
117 Kendrick Street, Suite 500
Cambridge MASSACHUSETTS 02494 US
CEO: Brian M. Stuglik
Employees: 73
Company Website: https://www.verastem.com/
Investor Relations: https://investor.verastem.com/events/
Phone: 17812924200
VSTM FAQ
What is the stock price of VSTM?
The current stock price of VSTM is 5.85 USD.
What is the symbol for VERASTEM INC stock?
The exchange symbol of VERASTEM INC is VSTM and it is listed on the Nasdaq exchange.
On which exchange is VSTM stock listed?
VSTM stock is listed on the Nasdaq exchange.
Is VSTM a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VSTM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VSTM.
Does VSTM stock pay dividends?
VSTM does not pay a dividend.
What is the Price/Earnings (PE) ratio of VSTM?
VSTM does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.19).
What is the Short Interest ratio of VSTM stock?
The outstanding short interest for VSTM is 11.94% of its float.
VSTM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VSTM. When comparing the yearly performance of all stocks, VSTM is a bad performer in the overall market: 68.97% of all stocks are doing better.
VSTM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VSTM. VSTM has a bad profitability rating. Also its financial health evaluation is rather negative.
VSTM Financial Highlights
Over the last trailing twelve months VSTM reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS decreased by 21.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.13% | ||
| ROE | -271.17% | ||
| Debt/Equity | 0.96 |
VSTM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to VSTM. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 26.17% and a revenue growth 76% for VSTM